Advertisement

Adaptive Resistance to Cancer Immunotherapy

  • A. J. Robert McGray
  • Jonathan Bramson
Chapter
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 1036)

Abstract

Immunosuppressive mechanisms within the tumor microenvironment have emerged as a major impediment to cancer immunotherapy. While a broad range of secreted factors, receptors/ligands, and cell populations have been described that contribute to the immunosuppression, the involvement of these processes in immune evasion by tumors is typically considered to be an intrinsic property of the tumor. Evidence is now emerging that the processes underlying immune suppression within the tumor are, in fact, triggered by immune attack and reflect a dynamic interplay between the tumor and the host’s immune system. The term adaptive resistance has been coined to describe the induction of immune suppressive pathways in the tumor following active attack on the tumor. Adaptive resistance is a scalable process where the magnitude of immune suppression matches the magnitude of the immune attack; the net balance between suppression and attack determines the durability of the anti-tumor response and tumor outcome. In this chapter, we will examine the data supporting adaptive resistance and the opposing roles of T cells in simultaneously promoting both anti-tumor immunity and immune suppression within the tumor microenvironment. The clinical implications of adaptive resistance in the design and application of immunotherapeutic strategies is also discussed.

Keywords

Adaptive resistance Immune suppression T Lymphocyte Tumor microenvironment Checkpoint blockade IFN-γ 

References

  1. 1.
    Rosenberg SA, Yang JC, Sherry RM, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-Cell transfer immunotherapy. Clin Cancer Res. 2011;17:4550–7.  https://doi.org/10.1158/1078-0432.CCR-11-0116.PubMedPubMedCentralCrossRefGoogle Scholar
  2. 2.
    Kalos M, Levine BL, Porter DL, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. 2011;3:95ra73.  https://doi.org/10.1126/scitranslmed.3002842.PubMedPubMedCentralCrossRefGoogle Scholar
  3. 3.
    Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Science. 2015;348:62–8.  https://doi.org/10.1126/science.aaa4967.PubMedCrossRefGoogle Scholar
  4. 4.
    Robbins PF, Kassim SH, Tran TLN, et al. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response. Clin Cancer Res. 2015;21:1019–27.  https://doi.org/10.1158/1078-0432.CCR-14-2708.PubMedCrossRefGoogle Scholar
  5. 5.
    Klebanoff CA, Gattinoni L, Palmer DC, et al. Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice. Clin Cancer Res. 2011;17:5343–52.  https://doi.org/10.1158/1078-0432.CCR-11-0503.PubMedPubMedCentralCrossRefGoogle Scholar
  6. 6.
    Overwijk WWW, Tsung AA, Irvine KRK, et al. gp100/pmel 17 is a murine tumor rejection antigen: induction of “self-”reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J Exp Med. 1998;188:277–86.PubMedPubMedCentralCrossRefGoogle Scholar
  7. 7.
    McGray AJR, Hallett R, Bernard D, et al. Immunotherapy-induced CD8+ T cells instigate immune suppression in the tumor. Mol Ther. 2014;22:206–18.  https://doi.org/10.1038/mt.2013.255.PubMedCrossRefGoogle Scholar
  8. 8.
    Dudley ME, Gross CA, Langhan MM, et al. CD8+ enriched “young” tumor infiltrating lymphocytes can mediate regression of metastatic melanoma. Clin Cancer Res. 2010;16:6122–31.  https://doi.org/10.1158/1078-0432.CCR-10-1297.PubMedPubMedCentralCrossRefGoogle Scholar
  9. 9.
    Wong SBJ, Bos R, Sherman LA. Tumor-specific CD4+ T cells render the tumor environment permissive for infiltration by low-avidity CD8+ T cells. J Immunol. 2008;180:3122–31.PubMedCrossRefGoogle Scholar
  10. 10.
    Bos R, Sherman LA. CD4+ T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8+ T lymphocytes. Cancer Res. 2010;70:8368–77.  https://doi.org/10.1158/0008-5472.CAN-10-1322.PubMedPubMedCentralCrossRefGoogle Scholar
  11. 11.
    Ray S, Chhabra A, Chakraborty NG, et al. MHC-I-restricted melanoma antigen specific TCR-engineered human CD4+ T cells exhibit multifunctional effector and helper responses, in vitro. Clin Immunol. 2010;136:338–47.  https://doi.org/10.1016/j.clim.2010.04.013.PubMedPubMedCentralCrossRefGoogle Scholar
  12. 12.
    Ding Z-C, Huang L, Blazar BR, et al. Polyfunctional CD4+ T cells are essential for eradicating advanced B-cell lymphoma after chemotherapy. Blood. 2012;120:2229–39.  https://doi.org/10.1182/blood-2011-12-398321.PubMedPubMedCentralCrossRefGoogle Scholar
  13. 13.
    Hung K, Hayashi R, Lafond-Walker A, et al. The central role of CD4(+) T cells in the antitumor immune response. J Exp Med. 1998;188:2357–68.PubMedPubMedCentralCrossRefGoogle Scholar
  14. 14.
    Mattes J, Hulett M, Xie W, et al. Immunotherapy of cytotoxic T cell-resistant tumors by T helper 2 cells: an eotaxin and STAT6-dependent process. J Exp Med. 2003;197:387–93.PubMedPubMedCentralCrossRefGoogle Scholar
  15. 15.
    Tran E, Turcotte S, Gros A, et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science. 2014;344:641–5.  https://doi.org/10.1126/science.1251102.PubMedCrossRefGoogle Scholar
  16. 16.
    Corthay A. Does the immune system naturally protect against cancer? Front Immunol. 2014;5:197.  https://doi.org/10.3389/fimmu.2014.00197.PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Chow MT, Möller A, Smyth MJ. Inflammation and immune surveillance in cancer. Semin Cancer Biol. 2012;22:23–32.  https://doi.org/10.1016/j.semcancer.2011.12.004.PubMedCrossRefGoogle Scholar
  18. 18.
    Dunn GP, Bruce AT, Ikeda H, et al. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002;3:991–8.  https://doi.org/10.1038/ni1102-991.PubMedCrossRefGoogle Scholar
  19. 19.
    Burnet M. Cancer: a biological approach. III. Viruses associated with neoplastic conditions. IV. Practical applications. Br Med J. 1957;1:841–7.PubMedPubMedCentralCrossRefGoogle Scholar
  20. 20.
    Stutman O. Tumor development after 3-methylcholanthrene in immunologically deficient athymic-nude mice. Science. 1974;183:534–6.PubMedCrossRefGoogle Scholar
  21. 21.
    Hünig T, Bevan MJ. Specificity of cytotoxic T cells from athymic mice. J Exp Med. 1980;152:688–702.PubMedCrossRefGoogle Scholar
  22. 22.
    Dighe AS, Richards E, Old LJ, Schreiber RD. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. Immunity. 1994;1:447–56.PubMedCrossRefGoogle Scholar
  23. 23.
    Kaplan DH, Shankaran V, Dighe AS, et al. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci U S A. 1998;95:7556–61.PubMedPubMedCentralCrossRefGoogle Scholar
  24. 24.
    Shankaran V, Ikeda H, Bruce AT, et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. 2001;410:1107–11.  https://doi.org/10.1038/35074122.PubMedCrossRefGoogle Scholar
  25. 25.
    van den Broek ME, Kägi D, Ossendorp F, et al. Decreased tumor surveillance in perforin-deficient mice. J Exp Med. 1996;184:1781–90.PubMedCrossRefGoogle Scholar
  26. 26.
    Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011;331:1565–70.  https://doi.org/10.1126/science.1203486.PubMedCrossRefGoogle Scholar
  27. 27.
    Dunn S. Cancer Immunoediting: from immuno-surveillance to tumor escape. Nat Immunol. 2002;3(11):991–8.Google Scholar
  28. 28.
    Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet. 2007;370:59–67.  https://doi.org/10.1016/S0140-6736(07)61050-2.PubMedCrossRefGoogle Scholar
  29. 29.
    Tiriveedhi V, Tucker N, Herndon J, et al. Safety and preliminary evidence of biologic efficacy of a mammaglobin-a DNA vaccine in patients with stable metastatic breast cancer. Clin Cancer Res. 2014;20:5964–75.  https://doi.org/10.1158/1078-0432.CCR-14-0059.PubMedPubMedCentralCrossRefGoogle Scholar
  30. 30.
    Odunsi K, Matsuzaki J, James SR, et al. Epigenetic potentiation of NY-ESO-1 vaccine therapy in human ovarian cancer. Cancer Immunol Res. 2014;2:37–49.  https://doi.org/10.1158/2326-6066.CIR-13-0126.PubMedPubMedCentralCrossRefGoogle Scholar
  31. 31.
    Schwartzentruber DJ, Lawson DH, Richards JM, et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med. 2011;364:2119–27.  https://doi.org/10.1056/NEJMoa1012863.PubMedPubMedCentralCrossRefGoogle Scholar
  32. 32.
    Odunsi KK, Matsuzaki JJ, Karbach JJ, et al. Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients. Proc Natl Acad Sci U S A. 2012;109:5797–802.  https://doi.org/10.1073/pnas.1117208109.PubMedPubMedCentralCrossRefGoogle Scholar
  33. 33.
    Hoos A, Eggermont AMM, Janetzki S, et al. Improved endpoints for cancer immunotherapy trials. JNCI. J Natl Cancer Inst. 2010;102:1388–97.  https://doi.org/10.1093/jnci/djq310.PubMedPubMedCentralCrossRefGoogle Scholar
  34. 34.
    Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus Ipilimumab in advanced melanoma. N Engl J Med. 2013;369:122–33.  https://doi.org/10.1056/NEJMoa1302369.PubMedPubMedCentralCrossRefGoogle Scholar
  35. 35.
    Topalian SL, Sznol M, McDermott DF, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014;32:1020–30.  https://doi.org/10.1200/JCO.2013.53.0105.PubMedPubMedCentralCrossRefGoogle Scholar
  36. 36.
    Robert C, Schachter J, Long GV, et al. Pembrolizumab versus Ipilimumab in advanced melanoma. N Engl J Med. 2015;372(26):2521–32.  https://doi.org/10.1056/NEJMoa1503093.PubMedCrossRefGoogle Scholar
  37. 37.
    MacKie RM, Reid R, Junor B. Fatal melanoma transferred in a donated kidney 16 years after melanoma surgery. N Engl J Med. 2003;348:567–8.  https://doi.org/10.1056/NEJM200302063480620.PubMedCrossRefGoogle Scholar
  38. 38.
    Campoli M, Ferrone S. HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance. Oncogene. 2008;27:5869–85.  https://doi.org/10.1038/onc.2008.273.PubMedPubMedCentralCrossRefGoogle Scholar
  39. 39.
    Garcia-Lora A, Martinez M, Algarra I, et al. MHC class I-deficient metastatic tumor variants immunoselected by T lymphocytes originate from the coordinated downregulation of APM components. Int J Cancer. 2003;106:521–7.  https://doi.org/10.1002/ijc.11241.PubMedCrossRefGoogle Scholar
  40. 40.
    Méndez R, Rodríguez T, Del Campo A, et al. Characterization of HLA class I altered phenotypes in a panel of human melanoma cell lines. Cancer Immunol Immunother. 2008;57:719–29.  https://doi.org/10.1007/s00262-007-0411-3.PubMedCrossRefGoogle Scholar
  41. 41.
    Seliger B. Novel insights into the molecular mechanisms of HLA class I abnormalities. Cancer Immunol Immunother. 2012;61:249–54.  https://doi.org/10.1007/s00262-011-1153-9.PubMedCrossRefGoogle Scholar
  42. 42.
    Lampen MH, van Hall T. Strategies to counteract MHC-I defects in tumors. Curr Opin Immunol. 2011;23:293–8.  https://doi.org/10.1016/j.coi.2010.12.005.PubMedCrossRefGoogle Scholar
  43. 43.
    Aptsiauri N, Carretero R, Garcia-Lora A, et al. Regressing and progressing metastatic lesions: resistance to immunotherapy is predetermined by irreversible HLA class I antigen alterations. Cancer Immunol Immunother. 2008;57:1727–33.  https://doi.org/10.1007/s00262-008-0532-3.PubMedCrossRefGoogle Scholar
  44. 44.
    Rolland P, Deen S, Scott I, et al. Human leukocyte antigen class I antigen expression is an independent prognostic factor in ovarian cancer. Clin Cancer Res. 2007;13:3591–6.  https://doi.org/10.1158/1078-0432.CCR-06-2087.PubMedCrossRefGoogle Scholar
  45. 45.
    Carretero R, Romero JM, Ruiz-Cabello F, et al. Analysis of HLA class I expression in progressing and regressing metastatic melanoma lesions after immunotherapy. Immunogenetics. 2008;60:439–47.  https://doi.org/10.1007/s00251-008-0303-5.PubMedCrossRefGoogle Scholar
  46. 46.
    Hicklin DJ, Wang Z, Arienti F, et al. beta2-Microglobulin mutations, HLA class I antigen loss, and tumor progression in melanoma. J Clin Invest. 1998;101:2720–9.  https://doi.org/10.1172/JCI498.PubMedPubMedCentralCrossRefGoogle Scholar
  47. 47.
    Jiménez P, Cantón J, Collado A, et al. Chromosome loss is the most frequent mechanism contributing to HLA haplotype loss in human tumors. Int J Cancer. 1999;83:91–7.PubMedCrossRefGoogle Scholar
  48. 48.
    Maleno I, López-Nevot MA, Cabrera T, et al. Multiple mechanisms generate HLA class I altered phenotypes in laryngeal carcinomas: high frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21. Cancer Immunol Immunother. 2002;51:389–96.  https://doi.org/10.1007/s00262-002-0296-0.PubMedCrossRefGoogle Scholar
  49. 49.
    Klippel ZK, Chou J, Towlerton AM, et al. Immune escape from NY-ESO-1-specific T-cell therapy via loss of heterozygosity in the MHC. Gene Ther. 2014;21:337–42.  https://doi.org/10.1038/gt.2013.87.PubMedPubMedCentralCrossRefGoogle Scholar
  50. 50.
    Khan ANH, Gregorie CJ, Tomasi TB. Histone deacetylase inhibitors induce TAP, LMP, Tapasin genes and MHC class I antigen presentation by melanoma cells. Cancer Immunol Immunother. 2008;57:647–54.  https://doi.org/10.1007/s00262-007-0402-4.PubMedCrossRefGoogle Scholar
  51. 51.
    Setiadi AF, Omilusik K, David MD, et al. Epigenetic enhancement of antigen processing and presentation promotes immune recognition of tumors. Cancer Res. 2008;68:9601–7.  https://doi.org/10.1158/0008-5472.CAN-07-5270.PubMedCrossRefGoogle Scholar
  52. 52.
    Martini M, Testi MG, Pasetto M, et al. IFN-gamma-mediated upmodulation of MHC class I expression activates tumor-specific immune response in a mouse model of prostate cancer. Vaccine. 2010;28:3548–57.  https://doi.org/10.1016/j.vaccine.2010.03.007.PubMedCrossRefGoogle Scholar
  53. 53.
    Mantovani A, Savino B, Locati M, et al. The chemokine system in cancer biology and therapy. Cytokine Growth Factor Rev. 2010;21:27–39.  https://doi.org/10.1016/j.cytogfr.2009.11.007.PubMedCrossRefGoogle Scholar
  54. 54.
    Mukaida N, Sasaki S-I, Baba T. Chemokines in cancer development and progression and their potential as targeting molecules for cancer treatment. Mediators Inflamm. 2014;2014:170381.  https://doi.org/10.1155/2014/170381.PubMedPubMedCentralCrossRefGoogle Scholar
  55. 55.
    Prestwich R, Errington F, Hatfield P, et al. The immune system—is it relevant to cancer development, progression and treatment? Clin Oncol. 2008;20:101–12.  https://doi.org/10.1016/j.clon.2007.10.011.CrossRefGoogle Scholar
  56. 56.
    Stewart TJ, Smyth MJ. Improving cancer immunotherapy by targeting tumor-induced immune suppression. Cancer Metastasis Rev. 2011;30:125–40.  https://doi.org/10.1007/s10555-011-9280-5.PubMedCrossRefGoogle Scholar
  57. 57.
    Li MO, Wan YY, Sanjabi S, et al. Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol. 2006;24:99–146.  https://doi.org/10.1146/annurev.immunol.24.021605.090737.PubMedCrossRefGoogle Scholar
  58. 58.
    Mocellin S, Marincola F, Rossi CR, et al. The multifaceted relationship between IL-10 and adaptive immunity: putting together the pieces of a puzzle. Cytokine Growth Factor Rev. 2004;15:61–76.PubMedCrossRefGoogle Scholar
  59. 59.
    Gorelik L, Flavell RA. Transforming growth factor-beta in T-cell biology. Nat Rev Immunol. 2002;2:46–53.  https://doi.org/10.1038/nri704.PubMedCrossRefGoogle Scholar
  60. 60.
    Pockaj BA, Basu GD, Pathangey LB, et al. Reduced T-cell and dendritic cell function is related to cyclooxygenase-2 overexpression and prostaglandin E2 secretion in patients with breast cancer. Ann Surg Oncol. 2004;11:328–39.PubMedCrossRefGoogle Scholar
  61. 61.
    Kalinski P. Regulation of immune responses by prostaglandin E2. J Immunol. 2012;188:21–8.  https://doi.org/10.4049/jimmunol.1101029.PubMedPubMedCentralCrossRefGoogle Scholar
  62. 62.
    Gabrilovich DI, Ishida T, Nadaf S, et al. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin Cancer Res. 1999;5:2963–70.PubMedGoogle Scholar
  63. 63.
    Stagg J, Smyth MJ. Extracellular adenosine triphosphate and adenosine in cancer. Oncogene. 2010;29:5346–58.  https://doi.org/10.1038/onc.2010.292.PubMedCrossRefGoogle Scholar
  64. 64.
    Jin D, Fan J, Wang L, et al. CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression. Cancer Res. 2010;70(6):2245–55. doi:  https://doi.org/10.1158/0008-5472.CAN-09-3109.
  65. 65.
    Deaglio S, Dwyer KM, Gao W, et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med. 2007;204:1257–65.  https://doi.org/10.1084/jem.20062512.PubMedPubMedCentralCrossRefGoogle Scholar
  66. 66.
    Lu T, Gabrilovich DI Molecular pathways: tumor-infiltrating myeloid cells and reactive oxygen species in regulation of tumor microenvironment. Clin Cancer Res. 2012;18(18):4877–82. doi:  https://doi.org/10.1158/1078-0432.CCR-11-2939.;
  67. 67.
    Bronte V, Kasic T, Gri G, et al. Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers. J Exp Med. 2005;201:1257–68.  https://doi.org/10.1084/jem.20042028.PubMedPubMedCentralCrossRefGoogle Scholar
  68. 68.
    Nagaraj S, Gupta K, Pisarev V, et al. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med. 2007;13:828–35.  https://doi.org/10.1038/nm1609.PubMedPubMedCentralCrossRefGoogle Scholar
  69. 69.
    Molon B, Ugel S, Del Pozzo F, et al. Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells. J Exp Med. 2011;208:1949–62.  https://doi.org/10.1084/jem.20101956.PubMedPubMedCentralCrossRefGoogle Scholar
  70. 70.
    Bronte V, Zanovello P. Regulation of immune responses by L-arginine metabolism. Nat Rev Immunol. 2005;5:641–54.  https://doi.org/10.1038/nri1668.PubMedCrossRefGoogle Scholar
  71. 71.
    Kropf P, Baud D, Marshall SE, et al. Arginase activity mediates reversible T cell hyporesponsiveness in human pregnancy. Eur J Immunol. 2007;37:935–45.  https://doi.org/10.1002/eji.200636542.PubMedPubMedCentralCrossRefGoogle Scholar
  72. 72.
    Terness P, Bauer TM, Röse L, et al. Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites. J Exp Med. 2002;196:447–57.PubMedPubMedCentralCrossRefGoogle Scholar
  73. 73.
    Grimm M, Kim M, Rosenwald A, et al. Tumour-mediated TRAIL-Receptor expression indicates effective apoptotic depletion of infiltrating CD8+ immune cells in clinical colorectal cancer. Eur J Cancer. 2010;46:2314–23.  https://doi.org/10.1016/j.ejca.2010.05.025.PubMedCrossRefGoogle Scholar
  74. 74.
    O’Connell J, Bennett MW, O’Sullivan GC, et al. The Fas counterattack: cancer as a site of immune privilege. Immunol Today. 1999;20:46–52.PubMedCrossRefGoogle Scholar
  75. 75.
    Motz GT, Santoro SP, Wang L-P, et al. Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat Med. 2014;20:607–15.  https://doi.org/10.1038/nm.3541.PubMedPubMedCentralCrossRefGoogle Scholar
  76. 76.
    Martin-Orozco N, Li Y, Wang Y, et al. Melanoma cells express ICOS ligand to promote the activation and expansion of T-regulatory cells. Cancer Res. 2010;70:9581–90.  https://doi.org/10.1158/0008-5472.CAN-10-1379.PubMedPubMedCentralCrossRefGoogle Scholar
  77. 77.
    Linsley PS, Bradshaw J, Greene J, et al. Intracellular trafficking of CTLA-4 and focal localization towards sites of TCR engagement. Immunity. 1996;4:535–43.PubMedCrossRefGoogle Scholar
  78. 78.
    Sharpe AH, Freeman GJ. The B7-CD28 superfamily. Nat Rev Immunol. 2002;2:116–26.  https://doi.org/10.1038/nri727.PubMedCrossRefGoogle Scholar
  79. 79.
    Onodera T, Jang MH, Guo Z, et al. Constitutive expression of IDO by dendritic cells of mesenteric lymph nodes: functional involvement of the CTLA-4/B7 and CCL22/CCR4 interactions. J Immunol. 2009;183:5608–14.  https://doi.org/10.4049/jimmunol.0804116.PubMedCrossRefGoogle Scholar
  80. 80.
    Fallarino F, Grohmann U, Hwang KW, et al. Modulation of tryptophan catabolism by regulatory T cells. Nat Immunol. 2003;4:1206–12.  https://doi.org/10.1038/ni1003.PubMedCrossRefGoogle Scholar
  81. 81.
    Jacobs JFM, Nierkens S, Figdor CG, et al. Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy? Lancet Oncol. 2012;13:e32–42.  https://doi.org/10.1016/S1470-2045(11)70155-3.PubMedCrossRefGoogle Scholar
  82. 82.
    Riella LV, Paterson AM, Sharpe AH, Chandraker A. Role of the PD-1 pathway in the immune response. Am J Transplant. 2012;12:2575–87.  https://doi.org/10.1111/j.1600-6143.2012.04224.x.PubMedPubMedCentralCrossRefGoogle Scholar
  83. 83.
    Taube JMJ, Anders RAR, Young GDG, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med. 2012;4:127ra37.  https://doi.org/10.1126/scitranslmed.3003689.PubMedPubMedCentralCrossRefGoogle Scholar
  84. 84.
    Pilon-Thomas S, Mackay A, Vohra N, Mulé JJ. Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma. J Immunol. 2010;184:3442–9.  https://doi.org/10.4049/jimmunol.0904114.PubMedPubMedCentralCrossRefGoogle Scholar
  85. 85.
    Wang B-J, Bao J-J, Wang J-Z, et al. Immunostaining of PD-1/PD-Ls in liver tissues of patients with hepatitis and hepatocellular carcinoma. World J Gastroenterol. 2011;17:3322–9.  https://doi.org/10.3748/wjg.v17.i28.3322.PubMedPubMedCentralCrossRefGoogle Scholar
  86. 86.
    Lesterhuis WJ, Punt CJ, Hato SV, et al. Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice. J Clin Invest. 2011;121:3100–8.  https://doi.org/10.1172/JCI43656DS1.PubMedPubMedCentralCrossRefGoogle Scholar
  87. 87.
    Ahmadzadeh M, Johnson LA, Heemskerk B, et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood. 2009;114:1537–44.  https://doi.org/10.1182/blood-2008-12-195792.PubMedPubMedCentralCrossRefGoogle Scholar
  88. 88.
    Ngiow SF, Teng MWL, Smyth MJ. Prospects for TIM3-targeted antitumor immunotherapy. Cancer Res. 2011;71:6567–71.  https://doi.org/10.1158/0008-5472.CAN-11-1487.PubMedCrossRefGoogle Scholar
  89. 89.
    Zhu C, Anderson AC, Schubart A, et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol. 2005;6:1245–52.  https://doi.org/10.1038/ni1271.PubMedCrossRefGoogle Scholar
  90. 90.
    Huard B, Prigent P, Tournier M, et al. CD4/major histocompatibility complex class II interaction analyzed with CD4- and lymphocyte activation gene-3 (LAG-3)-Ig fusion proteins. Eur J Immunol. 1995;25:2718–21.  https://doi.org/10.1002/eji.1830250949.PubMedCrossRefGoogle Scholar
  91. 91.
    Goldberg MV, Drake CG. LAG-3 in cancer immunotherapy. Curr Top Microbiol Immunol. 2011;344:269–78.  https://doi.org/10.1007/82_2010_114.PubMedPubMedCentralGoogle Scholar
  92. 92.
    Hannier S, Tournier M, Bismuth G, Triebel F. CD3/TCR complex-associated lymphocyte activation gene-3 molecules inhibit CD3/TCR signaling. J Immunol. 1998;161:4058–65.PubMedGoogle Scholar
  93. 93.
    Hemon P, Jean-Louis F, Ramgolam K, et al. MHC class II engagement by its ligand LAG-3 (CD223) contributes to melanoma resistance to apoptosis. J Immunol. 2011;186:5173–83.  https://doi.org/10.4049/jimmunol.1002050.PubMedCrossRefGoogle Scholar
  94. 94.
    Liang B, Workman C, Lee J, et al. Regulatory T cells inhibit dendritic cells by lymphocyte activation gene-3 engagement of MHC class II. J Immunol. 2008;180:5916–26.PubMedCrossRefGoogle Scholar
  95. 95.
    Sabatos CA, Chakravarti S, Cha E, et al. Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance. Nat Immunol. 2003;4:1102–10.  https://doi.org/10.1038/ni988.PubMedCrossRefGoogle Scholar
  96. 96.
    Sakuishi K, Apetoh L, Sullivan JM, et al. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med. 2010;207:2187–94.  https://doi.org/10.1084/jem.20100643.PubMedPubMedCentralCrossRefGoogle Scholar
  97. 97.
    Ngiow SF, Scheidt Von B, Akiba H, et al. Anti-TIM3 antibody promotes T Cell IFN-mediated antitumor immunity and suppresses established tumors. Cancer Res. 2011;71:3540–51.  https://doi.org/10.1158/0008-5472.CAN-11-0096.PubMedCrossRefGoogle Scholar
  98. 98.
    Zhou Q, Munger ME, Veenstra RG, et al. Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood. 2011;117:4501–10.  https://doi.org/10.1182/blood-2010-10-310425.PubMedPubMedCentralCrossRefGoogle Scholar
  99. 99.
    Woo S-R, Turnis ME, Goldberg MV, et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res. 2012;72:917–27.  https://doi.org/10.1158/0008-5472.CAN-11-1620.PubMedCrossRefGoogle Scholar
  100. 100.
    Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252–64.  https://doi.org/10.1038/nrc3239.PubMedPubMedCentralCrossRefGoogle Scholar
  101. 101.
    Taube JM, Young GD, McMiller TL, et al. Differential expression of immune-regulatory genes associated with PD-L1 display in melanoma: implications for PD-1 pathway blockade. Clin Cancer Res. 2015;21(17):3969–76. doi:  https://doi.org/10.1158/1078-0432.CCR-15-0244.
  102. 102.
    Kluger HM, Zito CR, Barr ML, et al. Characterization of PD-L1 expression and associated T-cell infiltrates in metastatic melanoma samples from variable anatomic sites. Clin Cancer Res. 2015;21(13):3052–60. doi:  https://doi.org/10.1158/1078-0432.CCR-14-3073.
  103. 103.
    Lyford-Pike S, Peng S, Young GD, et al. Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Cancer Res. 2013;73:1733–41.  https://doi.org/10.1158/0008-5472.CAN-12-2384.PubMedPubMedCentralCrossRefGoogle Scholar
  104. 104.
    Dolen Y, Esendagli G. Myeloid leukemia cells with a B7-2(+) subpopulation provoke Th-cell responses and become immuno-suppressive through the modulation of B7 ligands. Eur J Immunol. 2013;43:747–57.  https://doi.org/10.1002/eji.201242814.PubMedCrossRefGoogle Scholar
  105. 105.
    Spranger S, Spaapen RM, Zha Y, et al. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med. 2013;5:200ra116.  https://doi.org/10.1126/scitranslmed.3006504.PubMedPubMedCentralCrossRefGoogle Scholar
  106. 106.
    Hosoi A, Matsushita H, Shimizu K, et al. Adoptive cytotoxic T lymphocyte therapy triggers a counter-regulatory immunosuppressive mechanism via recruitment of myeloid-derived suppressor cells. Int J Cancer. 2014;134:1810–22.  https://doi.org/10.1002/ijc.28506.PubMedCrossRefGoogle Scholar
  107. 107.
    Wong JL, Obermajer N, Odunsi K, et al. Synergistic COX2 induction by IFN and TNF self-limits Type-1 immunity in the human tumor microenvironment. Cancer Immunol Res. 2016;4:303–11.  https://doi.org/10.1158/2326-6066.CIR-15-0157.PubMedPubMedCentralCrossRefGoogle Scholar
  108. 108.
    Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515:568–71.  https://doi.org/10.1038/nature13954.PubMedPubMedCentralCrossRefGoogle Scholar
  109. 109.
    McGray AJR, Bernard D, Hallett R, et al. Combined vaccination and immunostimulatory antibodies provides durable cure of murine melanoma and induces transcriptional changes associated with positive outcome in human melanoma patients. Oncoimmunology. 2012;1:419–31.PubMedPubMedCentralCrossRefGoogle Scholar
  110. 110.
    Gajewski TF. Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment. Clin Cancer Res. 2007;13:5256–61.  https://doi.org/10.1158/1078-0432.CCR-07-0892.PubMedCrossRefGoogle Scholar
  111. 111.
    Gajewski TF, Fuertes M, Spaapen R, et al Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment. Curr Opin Immunol. 2010;23(2):286–92. doi:  https://doi.org/10.1016/j.coi.2010.11.013.
  112. 112.
    Gajewski TF. Molecular profiling of melanoma and the evolution of patient-specific therapy. Semin Oncol. 2011;38:236–42.  https://doi.org/10.1053/j.seminoncol.2011.01.004.PubMedPubMedCentralCrossRefGoogle Scholar
  113. 113.
    Gajewski TF. Cancer immunotherapy. Mol Oncol. 2012;6:242–50.  https://doi.org/10.1016/j.molonc.2012.01.002.PubMedPubMedCentralCrossRefGoogle Scholar
  114. 114.
    Gajewski TF, Woo S-R, Zha Y, et al. Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment. Curr Opin Immunol. 2013;25:268–76.  https://doi.org/10.1016/j.coi.2013.02.009.PubMedCrossRefGoogle Scholar
  115. 115.
    Woo S-R, Corrales L, Gajewski TF. The STING pathway and the T cell-inflamed tumor microenvironment. Trends Immunol. 2015;36:250–6.  https://doi.org/10.1016/j.it.2015.02.003.PubMedPubMedCentralCrossRefGoogle Scholar
  116. 116.
    Baniyash M (2006) Chronic inflammation, immunosuppression and cancer: new insights and outlook. Seminars in Cancer Biology.Google Scholar
  117. 117.
    Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol. 2009;182:4499–506.  https://doi.org/10.4049/jimmunol.0802740.PubMedPubMedCentralCrossRefGoogle Scholar
  118. 118.
    Umansky V, Sevko A. Overcoming immunosuppression in the melanoma microenvironment induced by chronic inflammation. Cancer Immunol Immunother. 2012;61:275–82.  https://doi.org/10.1007/s00262-011-1164-6.PubMedCrossRefGoogle Scholar
  119. 119.
    Kanterman J, Sade-Feldman M, Baniyash M. New insights into chronic inflammation-induced immunosuppression. Semin Cancer Biol. 2012;22:307–18.  https://doi.org/10.1016/j.semcancer.2012.02.008.PubMedCrossRefGoogle Scholar
  120. 120.
    Baniyash M, Sade-Feldman M, Kanterman J. Chronic inflammation and cancer: suppressing the suppressors. Cancer Immunol Immunother. 2014;63:11–20.  https://doi.org/10.1007/s00262-013-1468-9.PubMedCrossRefGoogle Scholar
  121. 121.
    Wang J, Yoshida T, Nakaki F, Hiai H. Establishment of NOD-Pdcd1−/−mice as an efficient animal model of type I diabetes. Proc Natl Acad Sci U S A. 2005;102(33):11823–8.Google Scholar
  122. 122.
    Guleria I. A critical role for the programmed death ligand 1 in fetomaternal tolerance. J Exp Med. 2005;202:231–7.  https://doi.org/10.1084/jem.20050019.PubMedPubMedCentralCrossRefGoogle Scholar
  123. 123.
    Habicht AA, Dada SS, Jurewicz MM, et al. A link between PDL1 and T regulatory cells in fetomaternal tolerance. J Immunol. 2007;179:5211–9.PubMedCrossRefGoogle Scholar
  124. 124.
    Zhang Y, Chung Y, Bishop C, et al. Regulation of T cell activation and tolerance by PDL2. Proc Natl Acad Sci U S A. 2006;103:11695–700.  https://doi.org/10.1073/pnas.0601347103.PubMedPubMedCentralCrossRefGoogle Scholar
  125. 125.
    Matsumoto KK, Inoue HH, Nakano TT, et al. B7-DC regulates asthmatic response by an IFN-gamma-dependent mechanism. J Immunol. 2004;172:2530–41.PubMedCrossRefGoogle Scholar
  126. 126.
    Okazaki T, Okazaki I-M, Wang J, et al. PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice. J Exp Med. 2011;208:395–407.  https://doi.org/10.1084/jem.20100466.PubMedPubMedCentralCrossRefGoogle Scholar
  127. 127.
    Liu Y, Shu Q, Gao L, et al. Increased Tim-3 expression on peripheral lymphocytes from patients with rheumatoid arthritis negatively correlates with disease activity. Clin Immunol. 2010;137:288–95.  https://doi.org/10.1016/j.clim.2010.07.012.PubMedCrossRefGoogle Scholar
  128. 128.
    Keir ME, Freeman GJ, Sharpe AH. PD-1 regulates self-reactive CD8+ T cell responses to antigen in lymph nodes and tissues. J Immunol. 2007;179:5064–70.PubMedCrossRefGoogle Scholar
  129. 129.
    Dalton DK, Wittmer S. Nitric-oxide-dependent and independent mechanisms of protection from CNS inflammation during Th1-mediated autoimmunity: evidence from EAE in iNOS KO mice. J Neuroimmunol. 2005;160:110–21.  https://doi.org/10.1016/j.jneuroim.2004.11.004.PubMedCrossRefGoogle Scholar
  130. 130.
    Yaswen L, Kulkarni AB, Fredrickson T, et al. Autoimmune manifestations in the transforming growth factor-beta 1 knockout mouse. Blood. 1996;87:1439–45.PubMedGoogle Scholar
  131. 131.
    Shull MM, Ormsby I, Kier AB, et al. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature. 1992;359:693–9.  https://doi.org/10.1038/359693a0.PubMedPubMedCentralCrossRefGoogle Scholar
  132. 132.
    Pallotta MTM, Orabona CC, Volpi CC, et al. Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells. Nat Immunol. 2011;12:870–8.  https://doi.org/10.1038/ni.2077.PubMedCrossRefGoogle Scholar
  133. 133.
    Fallarino FF, Grohmann UU, Puccetti PP. Indoleamine 2,3-dioxygenase: From catalyst to signaling function. Eur J Immunol. 2012;42:1932–7.  https://doi.org/10.1002/eji.201242572.PubMedCrossRefGoogle Scholar
  134. 134.
    Vermeire KK, Heremans HH, Vandeputte MM, et al. Accelerated collagen-induced arthritis in IFN-gamma receptor-deficient mice. J Immunol. 1997;158:5507–13.PubMedGoogle Scholar
  135. 135.
    Ferber IA, Brocke S, Taylor-Edwards C. Mice with a disrupted IFN-gamma gene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE). J Immunol. 1996;156(1):5–7.Google Scholar
  136. 136.
    Krakowski MM, Owens TT. Interferon-gamma confers resistance to experimental allergic encephalomyelitis. Eur J Immunol. 1996;26:1641–6.  https://doi.org/10.1002/eji.1830260735.PubMedCrossRefGoogle Scholar
  137. 137.
    Tran EHE, Prince ENE, Owens TT. IFN-gamma shapes immune invasion of the central nervous system via regulation of chemokines. J Immunol. 2000;164:2759–68.PubMedCrossRefGoogle Scholar
  138. 138.
    Ring GHG, Dai ZZ, Saleem SS, et al. Increased susceptibility to immunologically mediated glomerulonephritis in IFN-gamma-deficient mice. J Immunol. 1999;163:2243–8.PubMedGoogle Scholar
  139. 139.
    Zaidi MR, Merlino G. The two faces of interferon- in cancer. Clin Cancer Res. 2011;17:6118–24.  https://doi.org/10.1158/1078-0432.CCR-11-0482.PubMedPubMedCentralCrossRefGoogle Scholar
  140. 140.
    Yang JC, Hughes M, Kammula U, et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother. 2007;30:825–30.  https://doi.org/10.1097/CJI.0b013e318156e47e.PubMedPubMedCentralCrossRefGoogle Scholar
  141. 141.
    Hodi FSF, O’Day SJS, McDermott DFD, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–23.  https://doi.org/10.1056/NEJMoa1003466.PubMedPubMedCentralCrossRefGoogle Scholar
  142. 142.
    Robert CC, Thomas LL, Bondarenko II, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364:2517–26.  https://doi.org/10.1056/NEJMoa1104621.PubMedCrossRefGoogle Scholar
  143. 143.
    Lynch TJT, Bondarenko II, Luft AA, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol. 2012;30:2046–54.  https://doi.org/10.1200/JCO.2011.38.4032.PubMedCrossRefGoogle Scholar
  144. 144.
    Brahmer JRJ, Drake CGC, Wollner II, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010;28:3167–75.  https://doi.org/10.1200/JCO.2009.26.7609.PubMedPubMedCentralCrossRefGoogle Scholar
  145. 145.
    Topalian SLS, Hodi FSF, Brahmer JRJ, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443–54.  https://doi.org/10.1056/NEJMoa1200690.PubMedPubMedCentralCrossRefGoogle Scholar
  146. 146.
    Brahmer JRJ, Tykodi SSS, Chow LQML, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366:2455–65.  https://doi.org/10.1056/NEJMoa1200694.PubMedPubMedCentralCrossRefGoogle Scholar
  147. 147.
    Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018–28. doi:  https://doi.org/10.1056/NEJMoa1501824.
  148. 148.
    Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348:56–61.  https://doi.org/10.1126/science.aaa8172.PubMedCrossRefGoogle Scholar
  149. 149.
    Postow MA, Chesney J, Pavlick AC, et al (2015) Nivolumab and Ipilimumab versus Ipilimumab in untreated melanoma. N Engl J Med. 2015;372(21):2006–17. doi:  https://doi.org/10.1056/NEJMoa1414428.
  150. 150.
    Curran MA, Montalvo W, Yagita H, Allison JP. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A. 2010;107:4275–80.  https://doi.org/10.1073/pnas.0915174107.PubMedPubMedCentralCrossRefGoogle Scholar
  151. 151.
    Duraiswamy J, Kaluza KM, Freeman GJ, Coukos G. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res. 2013;73:3591–603.  https://doi.org/10.1158/0008-5472.CAN-12-4100.PubMedPubMedCentralCrossRefGoogle Scholar
  152. 152.
    Winograd R, Byrne KT, Evans RA, et al. Induction of T-cell immunity overcomes complete resistance to PD-1 and CTLA-4 blockade and improves survival in pancreatic carcinoma. Cancer Immunol Res. 2015;3:399–411.  https://doi.org/10.1158/2326-6066.CIR-14-0215.PubMedPubMedCentralCrossRefGoogle Scholar
  153. 153.
    Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined Nivolumab and Ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(13):1270–1. doi:  https://doi.org/10.1056/NEJMoa1504030.
  154. 154.
    Baitsch L, Legat A, Barba L, et al. Extended co-expression of inhibitory receptors by human CD8 T-cells depending on differentiation, antigen-specificity and anatomical localization. PLoS One. 2012;7:e30852.  https://doi.org/10.1371/journal.pone.0030852.PubMedPubMedCentralCrossRefGoogle Scholar
  155. 155.
    Matsuzaki J, Gnjatic S, Mhawech-Fauceglia P, et al. Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci U S A. 2010;107:7875–80.  https://doi.org/10.1073/pnas.1003345107.PubMedPubMedCentralCrossRefGoogle Scholar
  156. 156.
    Blackburn SD, Shin H, Haining WN, et al. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol. 2009;10:29–37.  https://doi.org/10.1038/ni.1679.PubMedCrossRefGoogle Scholar
  157. 157.
    Fourcade J, Sun Z, Pagliano O, et al. PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8+ T cells induced by melanoma vaccines. Cancer Res. 2014;74:1045–55.  https://doi.org/10.1158/0008-5472.CAN-13-2908.PubMedCrossRefGoogle Scholar
  158. 158.
    Twyman-Saint Victor C, Rech AJ, Maity A, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 2015;520:373–7.  https://doi.org/10.1038/nature14292.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  1. 1.Center for ImmunotherapyRoswell Park Cancer InstituteBuffaloUSA
  2. 2.Department of Pathology and Molecular MedicineMcMaster UniversityHamiltonCanada

Personalised recommendations